Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SV-BR-1-GM Regimen and Retifanlimab in Metastatic or Locally Recurrent Breast Cancer
NCT03328026Phase 2Completed
- Sponsor
- BriaCell Therapeutics Corp.
- Start
- Mar 2018
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of SV-BR-1-GM, retifanlimab in breast cancer, sponsored by BriaCell Therapeutics Corp.. Started Mar 2018; status: completed.
02
Drugs
SV-BR-1-GMretifanlimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03328026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328026.